Can Macrobid (Nitrofurantoin) cause yeast infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Macrobid Cause Yeast Infections?

Yes, Macrobid (nitrofurantoin) can cause yeast infections as a recognized adverse effect of antibiotic therapy, though this occurs through disruption of normal vaginal flora rather than as a direct toxic effect of the drug itself.

Mechanism and Clinical Context

Nitrofurantoin, like other broad-spectrum antibiotics, disrupts the normal bacterial flora that maintains the vaginal ecosystem. 1 The FDA drug label for nitrofurantoin explicitly lists "superinfections caused by resistant organisms, e.g., Pseudomonas species or Candida species" as a recognized adverse reaction. 1

Repeat courses of antibiotics, including nitrofurantoin used for recurrent UTI prophylaxis, put patients at risk for yeast vaginitis. 2 This is a well-documented clinical concern in women receiving continuous or intermittent antibiotic prophylaxis for recurrent urinary tract infections.

Clinical Significance

  • Approximately 75% of women will experience at least one episode of vulvovaginal candidiasis (VVC) during their lifetime, with 40-45% experiencing two or more episodes. 3

  • The risk increases with antibiotic exposure because antibiotics eliminate protective Lactobacillus species that normally maintain vaginal pH and prevent Candida overgrowth. 2

  • This is particularly relevant for women on long-term nitrofurantoin prophylaxis (6-12 months) for recurrent UTIs, as recommended by guidelines. 2

Recognition and Management

Symptoms of post-antibiotic yeast infection include:

  • Vulvovaginal itching, burning, redness, and soreness
  • Thick white vaginal discharge resembling cottage cheese
  • Normal vaginal pH (<4.5) distinguishes this from bacterial vaginosis 3

First-line treatment options include:

  • Fluconazole 150 mg oral tablet as a single dose 3
  • Topical azole therapy (clotrimazole 1% cream or miconazole 2% cream intravaginally for 7-14 days) 3

Prevention Strategies

For women on long-term nitrofurantoin prophylaxis who develop recurrent yeast infections:

  • Consider intravaginal probiotics containing Lactobacillus rhamnosus GR-1 or Lactobacillus reuteri RC-14 once or twice weekly. 2

  • Counsel patients to recognize early symptoms and seek treatment promptly. 3

  • Women should return for follow-up if symptoms persist after OTC treatment or recur within 2 months. 3

Important Clinical Caveat

While yeast infections are a recognized complication of nitrofurantoin therapy, they should not automatically preclude its use for appropriate indications. Nitrofurantoin remains an effective agent for UTI prophylaxis with a favorable safety profile compared to other antibiotics, particularly regarding antimicrobial resistance. 4, 5 The benefit of preventing recurrent UTIs typically outweighs the manageable risk of occasional yeast infections, which can be treated effectively when they occur.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Yeast Infection After Antibiotic Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Nitrofurantoin: an update.

Obstetrical & gynecological survey, 1989

Research

Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.